$47.36
2.43% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US23282W6057
Symbol
CYTK

Cytokinetics, Incorporated Stock price

$47.36
-4.86 9.31% 1M
-6.42 11.94% 6M
-36.13 43.27% YTD
-36.08 43.24% 1Y
+1.51 3.29% 3Y
+37.07 360.25% 5Y
+40.69 610.05% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-1.18 2.43%
ISIN
US23282W6057
Symbol
CYTK
Sector
Industry

Key metrics

Market capitalization $5.59b
Enterprise Value $5.37b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1,666.68
P/S ratio (TTM) P/S ratio 1,735.76
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -58.81%
Revenue (TTM) Revenue $3.22m
EBIT (operating result TTM) EBIT $-524.63m
Free Cash Flow (TTM) Free Cash Flow $-407.05m
Cash position $1.01b
EPS (TTM) EPS $-5.39
P/E forward negative
P/S forward 1,635.87
EV/Sales forward 1,570.77
Short interest 18.14%
Show more

Is Cytokinetics, Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Cytokinetics, Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Cytokinetics, Incorporated forecast:

14x Buy
78%
4x Hold
22%

Analyst Opinions

18 Analysts have issued a Cytokinetics, Incorporated forecast:

Buy
78%
Hold
22%

Financial data from Cytokinetics, Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3.22 3.22
59% 59%
100%
- Direct Costs 13 13
33% 33%
419%
-10 -10
337% 337%
-319%
- Selling and Administrative Expenses 184 184
6% 6%
5,702%
- Research and Development Expense 317 317
2% 2%
9,853%
-511 -511
5% 5%
-15,874%
- Depreciation and Amortization 13 13
33% 33%
419%
EBIT (Operating Income) EBIT -525 -525
6% 6%
-16,293%
Net Profit -576 -576
9% 9%
-17,901%

In millions USD.

Don't miss a Thing! We will send you all news about Cytokinetics, Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cytokinetics, Incorporated Stock News

Neutral
GlobeNewsWire
6 days ago
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The MAA will now be reviewed by the Committee for ...
Positive
The Motley Fool
8 days ago
California-based biotech Cytokinetcs (CYTK 4.56%) finished the trading week in style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing deal in a key market abroad was the catalyst for the increase, which well exceeded the slightly over 1% gain of the S&P 500 index.
Neutral
GlobeNewsWire
9 days ago
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten is a next-in-class cardiac my...
More Cytokinetics, Incorporated News

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Head office United States
CEO Robert Blum
Employees 423
Founded 1997
Website www.cytokinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today